Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QR-110 phase 2 trial in CEP290-related Leber congenital amaurosis
NL-OMON55773Phase 2Completed
- Sponsor
- ProQR Therapeutics
- Start
- Nov 2019
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sepofarsen in Leber congenital amaurosis (LCA) (3 arms), sponsored by ProQR Therapeutics. Primary endpoint: Change from baseline in best-corrected visual acuity at 12 months versus sham. Started Nov 2019; status: completed.
02
Drugs
sepofarsen
03
Conditions
Leber congenital amaurosis (LCA)
Beyond the preview
Go deeper on NL-OMON55773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55773.